Long-term use of pioglitazone may be associated with liver dysfunction, heart failure, edema, hypoglycemia, rhabdomyolysis, gastric ulcer recurrence, anemia, and fractures. Pioglitazone is a thiazolidinedione hypoglycemic drug for patients with type 2 diabetes whose blood sugar cannot be controlled by exercise and diet therapy or is poorly controlled by the addition of other oral hypoglycemic drugs, which reduces peripheral and hepatic insulin resistance and decreases hepatic glycogen output. Prolonged use may lead to liver dysfunction, heart failure, edema, hypoglycemia, rhabdomyolysis, recurrence of gastric ulcers, anemia, fractures and other hazards. It is contraindicated in patients with hypersensitivity to pioglitazone, pregnancy, severe hepatic and renal dysfunction, heart failure, severe infections, type 1 diabetes, diabetic ketoacidosis. It is recommended that patients who need to take pioglitazone go to a regular hospital and use the drug under the guidance of a doctor, do not take the drug blindly on your own, so as not to delay the condition or lead to adverse reactions.